Ausbiz interview on brain cancer research  
 
    Proactive Investors interview: First trial for SOF-SKN™  
 
    Ausbiz interview on HERACLES trial  
 
    Chief Executive Officer Letter  
 
    Noxopharm 2023 AGM Corporate Presentation  
 
    Noxopharm talks partnership with Hudson Institute of Medical Research  
 
    Noxopharm hails new Sofra™ drug inflammation results  
 
    Noxopharm 2022 AGM Corporate Presentation  
 
    Ausbiz interview regarding pancreatic cancer research  
 
    Noxopharm reveals encouraging new pancreatic cancer preclinical study data  
 
    Noxopharm New Corporate Presentation June 2022